| 112 | 2 | 40 |
| 下载次数 | 被引频次 | 阅读次数 |
目的探讨托烷司琼预防甲状腺癌术后头痛及恶心呕吐等不良反应的临床效果。方法选择在2014年7月至2016年1月期间就诊的甲状腺癌手术患者90例,按照随机数字表法分为观察组及对照组,各45例。观察组采用托烷司琼预防头痛及恶心呕吐,对照组仅注射生理盐水,对比2组患者的头痛以及恶心呕吐的发生率。结果 2组患者的术前和术中情况差异无统计学意义(P> 0. 05);术后6、12h观察组头痛发生率分别为26. 7%、17. 8%,低于对照组的55. 6%、37. 8%,差异具有统计学意义(P <0. 05);术后6、12 h观察组恶心呕吐发生率分别为22. 2%、8. 9%,低于对照组的46. 7%、20. 0%,差异也具有统计学意义(P <0. 05)。结论甲状腺癌术后给予托烷司琼可以显著改善患者的头痛和恶心呕吐的发生状况,增加患者的舒适度。
Abstract：AIM To evaluate the clinical efficacy of tropisetron in preventing postoperative adverse reactions such as headache,nausea and vomiting of thyroid carcinoma. METHODS Ninety patients with thyroid carcinoma treated from July 2014 to January 2016 were selected and divided into observation group and control group according to random number table. In the observation group,tropisetron was used to prevent vomiting.In the control group,only saline was injected. The incidence of headache,nausea and vomiting between the 2groups was compared. RESULTS There was no significant difference between the 2 groups before and during operation(P > 0. 05). The incidence of headache in the observation group was 26. 7 % and 17. 8 % at 6 h and 12 h after operation,which was significantly lower than that of the control group(55. 6 % and 37. 8 %,P < 0. 05). The incidence of nausea and vomiting in the observation group was 22. 2% and 8. 9%,significantly lower than that in the control group at 6 h and 12 h after operation,and the difference was statistically significant(P < 0. 05). CONCLUSION Tropisetron can significantly improve headache,nausea and vomiting in patients with the occurrence of increased comfort.
[1]高艳,汪业铭,王丽,等.甘露醇联合托烷司琼预防甲状腺术后头痛及恶心呕吐的临床观察[J].临床麻醉学杂志,2015,31(10):1025.
[2]边春鸽,赵巧英.托烷司琼加镇静剂对减轻乳腺癌化疗所致恶心呕吐的效果评价[J].中国实用护理杂志,2014,30(3):54.
[3]HAJ-MIRZAIAN A,KORDJAZY N,AMIRI S,et al. Involvement of nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of tropisetron and ondansetron in mice forced swimming test and tail suspension test[J]. Eur J Pharmacol,2016,780:71.
[4]RAHIMIAN R,ZIRAK M R,KESHAVARZ M,et al. Involvement of PPARγin the protective action of tropisetron in an experimental model of ulcerative colitis[J]. Immunopharmacol Immunotoxicol.2016,20:1.
[5]LIU F C,LEE H C,LIAO C C,et al. Tropisetron Protects Against Acetaminophen-Induced Liver Injury via Suppressing Hepatic Oxidative Stress and Modulating the Activation of JNK/ERK MAPK Pathways[J]. Biomed Res Int,2016,2016:1952947.
[6]吴海波,许迎丽,刘昱升,等.托烷司琼联合按压内关穴治疗妇科腹腔镜术后复苏期恶心呕吐的疗效观察[J].护理研究,2016,30(19):2416.
[7]柴琴.帕洛诺司琼和托烷司琼预防化疗药物所致恶心呕吐临床疗效观察[J].临床肺科杂志,2015(6):1004.
[8]杜长黄.戊乙奎醚复合托烷司琼预防腹腔镜胆囊切除术后恶心呕吐的效果观察[J].蚌埠医学院学报,2014,39(4):476.
[9]康艳霞,闵婕,张东伟,等.阿瑞匹坦联合托烷司琼预防高致吐化疗药物引起恶心呕吐的临床研究[J].现代肿瘤医学,2016,24(12):1946.
[10]ABDEL MESSIH H A,ISHAK R A. Nanoethosomes for transdermal delivery of tropisetron HCl:multi-factorial predictive modeling,characterization and ex-vivo skin permeation[J]. Drug Dev Ind Pharm,2017,25:1.
[11]BELL G C,CAUDLE K E,WHIRL-CARRILLO M,et al. Clinical Pharmacogenetics Implementation Consortium(CPIC)guideline for CYP2D6 genotype and use of ondansetron and tropisetron[J]. Clin Pharmacol Ther,2017,102(2):213.
[12]孙媛媛,谢军,鲍健,等.托烷司琼联合地塞米松预防顺铂化疗所致恶心呕吐的临床研究[J].安徽医学,2014(3):282.
[13]STEGEMANN A,BHM M. Theα7 nicotinic acetylcholine receptor agonist tropisetron counteracts ultraviolet a-mediated oxidative stress in human dermal fibroblasts[J]. Exp Dermatol,2016,25(12):994.
[14]高艳.甘露醇联合托烷司琼预防甲状腺术后头痛头晕及恶心呕吐的临床观察[D].石家庄:河北医科大学,2015.
[15]李运,赵楠,方波,等.甲泼尼龙复合托烷司琼对术后恶心呕吐高危的甲状腺手术患者的预防作用[J].医学临床研究,2016,33(10):1896.
基本信息:
DOI：10.19577/j.1007-4406.2018.06.002
中图分类号:R736.1
引用信息:
[1]孙少华,沈丰,周文波,等.托烷司琼预防甲状腺癌术后不良反应的临床观察[J].中国临床药学杂志,2018,27(06):377-380.DOI:10.19577/j.1007-4406.2018.06.002.
基金信息:
湖北省卫生和计划生育委员会科研项目(编号WJ2015MB125)
2018-11-25
2018-11-25